• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Paul G. Richardson, MBBS

Publications

  • Guo C, Linton A, Jalaie M, Kephart S, Ornelas M, Pairish M, Greasley S, Richardson P, Maegley K, Hickey M, Li J, Wu X, Ji X, Xie Z.Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators.Bioorg Med Chem Lett. 2013 Jun 1;23(11):3358-63.
    23622982
  • Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM.Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration.Biol Blood Marrow Transplant. 2013 Mar 29.
    23545332
  • Richardson PG, Ho VT, Giralt S, Arai S, Mineishi S, Cutler C, Antin JH, Stavitzski N, Niederwieser D, Holler E, Carreras E, Soiffer R.Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.Ther Adv Hematol. 2012 Aug;3(4):253-65.
    23606935
  • O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Cancer Chemother Pharmacol. 2013 Apr 16.
    23589314
  • Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC.Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.Leuk Res. 2013 Apr 9.
    23582718
  • Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi NC, Richardson PG, Lewensohn R, Anderson KC.In vitro and In vivo Antitumor Activity of a Novel Alkylating Agent Melphalan-flufenamide Against Multiple Myeloma Cells.Clin Cancer Res. 2013 Apr 12.
    23584492
  • Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC.Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.Blood. 2013 Apr 11;121(15):2975-87.
    23321256
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.Blood. 2013 Mar 14;121(11):1961-7.
    23243282
  • Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Blood. 2013 Feb 21;121(8):1296-303.
    23287861
  • Voorhees PM, Laubach J, Anderson KC, Richardson PG.Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.Blood. 2013 Jan 31;121(5):858.
    23372151
  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG.Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.J Clin Oncol. 2013 Feb 1;31(4):448-55.
    23233713
  • Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P.Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.British Journal of Haematology. 2013 Feb;160(3):351-8.
    23240658
  • Richardson PG, Corbacioglu S, Ho VT, Kernan NA, Lehmann L, Maguire C, Maglio M, Hoyle M, Sardella M, Giralt S, Holler E, Carreras E, Niederwieser D, Soiffer R.Drug safety evaluation of defibrotide.Expert Opin Drug Saf. 2013 Jan;12(1):123-36.
    23228043
  • Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC.Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.Blood. 2012 Nov 8;120(19):3958-67.
    22983447
  • Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.Blood. 2012 Oct 25;120(17):3519-29.
    22955917
  • Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS.Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.British Journal of Haematology. 2012 Nov;159(3):340-51.
    22970818
  • Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC.Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.Blood. 2012 Sep 27.
    23018640
  • Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T, Anderson KC.New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors.Curr Pharm Des. 2012 Sep 26.
    23016853
  • van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG.How I treat plasma cell leukemia.Blood. 2012 Sep 20;120(12):2376-89.
    22837533
  • Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC.A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Cancer Cell. 2012 Sep 11;22(3):345-58.
    22975377
  • van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Cancer Management and Research. 2012;4:253-68.
    22956884
  • Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.Clin Cancer Res. 2012 Sep 1;18(17):4669-81.
    22806876
  • Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.Blood. 2012 Aug 30;120(9):1877-87.
    22689860
  • Wang Y, Lomakin A, Hideshima T, Laubach JP, Ogun O, Richardson PG, Munshi NC, Anderson KC, Benedek GB.Pathological crystallization of human immunoglobulins.Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13359-61.
    22847421
  • Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC.Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.British Journal of Haematology. 2012 Aug;158(4):472-80.
    22640031
  • Saboo SS, Fennessy F, Benajiba L, Laubach J, Anderson KC, Richardson PG.Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.J Clin Oncol. 2012 Jul 10;30(20):e175-9.
    22689802
  • Delforge M, Dhawan R, Robinson D, Meunier J, Regnault A, Esseltine DL, Cakana A, van de Velde H, Richardson PG, San Miguel JF.Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.Eur J Haematol. 2012 Jul;89(1):16-27.
    22469559
  • Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.Tanespimycin as antitumor therapy.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):17-22.
    21454186
  • Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC.A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.Blood. 2011 Mar 31.
    21454451
  • Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, Dimopoulos MA, Kropff M, Spicka I, Petrucci MT, Samoilova OS, Mateos MV, Magen-Nativ H, Goldschmidt H, Esseltine DL, Ricci DS, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF.Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.Eur J Haematol. 2011 Mar 2.
    21366694
  • Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen H, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, Lonial S.International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation.Blood. 2011 Mar 29.
    21447828
  • Laubach J, Richardson PG, Anderson K.Hematology: Setting the standard for newly diagnosed multiple myeloma.Nat Rev Clin Oncol. 2011 Mar 22.
    21423257
  • Lonial S, Mitsiades CS, Richardson PG.Treatment options for relapsed and refractory multiple myeloma.Clin Cancer Res. 2011 Mar 15;17(6):1264-77.
    21411442
  • Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG.Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.Lancet Oncol. 2011 Mar;12(3):263-72.
    21345726
  • Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P.A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.Proteomics. 2011 Feb 14.
    21365752
  • Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Expert Rev Hematol. 2011 Feb;4(1):51-60.
    21322778
  • Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.Blood. 2011 Feb 14.
    21321360
  • Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI.Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.Clin Chim Acta. 2011 Mar 18;412(7-8):562-8.
    21144845
  • Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, Mulligan G, Harousseau JL, Richardson PG, Ricci DS.Genetic variation associated with bortezomib-induced peripheral neuropathy.Pharmacogenet Genomics. 2011 Mar;21(3):121-9.
    21228734
  • Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J.Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.Blood. 2011 Feb 3.
    21292775
  • McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.British Journal of Haematology. 2011 Feb;152(4):420-32.
    21223249
  • Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.British Journal of Haematology. 2011 Feb;152(4):367-79. Review.
    21219297
  • Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.Blood. 2011 Jan 13;117(2):393-402.
    21030562
  • Richardson PG.A new standard of care in newly diagnosed multiple myeloma.Lancet. 2010 Dec 18;376(9758):2043-4.
    21146204
  • Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF.Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study.Eur J Haematol. 2011 Jan;86(1):23-31.
    20874823
  • Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC.A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma.Blood. 2010 Dec 2;116(23):4906-15.
    20805366
  • Richardson PG.Improving the therapeutic index in myeloma.Blood. 2010 Dec 2;116(23):4733-4.
    21127178
  • Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Rajkumar SV, Durie BG, San Miguel J.Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group.J Clin Oncol. 2010 Nov 20;28(33):4976-84. Review.
    20956629
  • Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF.Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.Blood. 2010 Nov 11;116(19):3743-50.
    20628153
  • Richardson PG.Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.Lancet Oncol. 2010 Nov;11(11):1014-6.
    21051016
  • Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.Blood. 2010 Oct 28;116(17):3227-37.
    20651070
  • Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.Am J Hematol. 2010 Sep;85(9):670-4.
    20652865
  • Ikeda H, Hideshima T, Fulciniti M, Perrone G, Mimura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cirstea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC.PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.Blood. 2010 Sep 2;116(9):1460-8.
    20505158
  • Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG.Kidney disease associated with plasma cell dyscrasias.Blood. 2010 Sep 2;116(9):1397-404. Review.
    20462963
  • Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC.Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.British Journal of Haematology. 2010 Aug;150(4):438-45.
    20618337
  • Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.British Journal of Haematology. 2010 Aug;150(4):428-37.
    20618338
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
    20385792
  • Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial.Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17.
    20167278
  • Rickles RJ, Pierce LT, Giordano TP, Tam WF, McMillin DW, Delmore J, Laubach JP, Borisy AA, Richardson PG, Lee MS.Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.Blood. 2010 Jul 29;116(4):593-602.
    20382846
  • Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH.Prediction Of Veno-Occlusive Disease Using Biomarkers Of Endothelial Injury.Biol Blood Marrow Transplant. 2010 Aug;16(8):1180-5.
    20184961
  • Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC.Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.Blood. 2010 Jul 1;115(26):5385-92.
    20395418
  • Laubach JP, Richardson PG, Anderson KC.The evolution and impact of therapy in multiple myeloma.Med Oncol. 2010 Jun;27 Suppl 1:S1-6. Review.
    20169425
  • Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J.Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.Clin Cancer Res. 2010 Jun 15;16(12):3260-9.
    20530693
  • Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, .Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.Leukemia. 2010 Jun;24(6):1121-7. Review.
    20410922
  • Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, Iacobelli M.The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.Blood Coagul Fibrinolysis. 2009 Dec;20(8):627-34.
    19809307
  • Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K.Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.Oncology (Huntingt). 2010 Mar;24(3 Suppl 2):22-9.
    20518367
  • Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC.A proto-oncogene Bcl-6 is upregulated in the bone marrow microenvironment in multiple myeloma cells.Blood. 2010 May 6;115(18):3772-5.
    20228272
  • Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.British Journal of Haematology. 2010 May;149(4):537-49.
    20331454
  • Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF.Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.J Clin Oncol. 2010 May 1;28(13):2259-66.
    20368561
  • McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS.Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.Nat Med. 2010 Apr;16(4):483-9.
    20228816
  • Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Craig Henderson I, Hurd DD, Peters WP, .Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local-Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082.Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1305-13.
    19747781
  • Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.J Clin Oncol. 2010 Mar 10;28(8):1408-14.
    20142598
  • Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.J Clin Oncol. 2010 Mar 10;28(8):1422-8.
    20142586
  • Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D.Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68. Review.
    19766729
  • Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K.Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12.
    20141673
  • Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.Clin Cancer Res. 2010 Feb 1;16(3):1033-41.
    20103671
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4.
    20118399
  • Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Blood. 2010 Jan 28;115(4):834-45.
    19965674
  • Stewart AK, Richardson PG, San-Miguel JF.How I treat multiple myeloma in younger patients.Blood. 2009 Dec 24;114(27):5436-43.
    19861683
  • Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia..
  • Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF.VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.J Clin Oncol. 2009 Dec 20;27(36):6086-93.
    19858394
  • Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.Clin Cancer Res. 2009 Dec 1;15(23):7153-60.
    19934289
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.J Clin Oncol. 2009 Dec 1;27(34):5713-9.
    19786667
  • Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS.In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.British Journal of Haematology. 2009 Dec;147(5):672-6.
    19751238
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
    19878638
  • Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.British Journal of Haematology. 2009 Nov;147(4):531-4.
    19725827
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw..
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer Cell. 2009 Oct 6;16(4):309-23.
    19800576
  • Laubach JP, Richardson PG, Anderson KC.Hematology: Thalidomide maintenance in multiple myeloma.Nat Rev Clin Oncol. 2009 Oct;6(10):565-6.
    19787000
  • Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV, .Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.Blood. 2009 Aug 27;114(9):1729-35.
    19561323
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Podar K, Hideshima T, Bianchi G, Mitsiades C, Raje N, Tai Y-T, Jaye DL, Kumar SK, Schlossman R, Richardson P, Munshi N, Anderson KC.Functional Interaction of plasmacytoid dendritic cells with multiple myeloma cells: a novel therapeutic target.Cancer Cell..
  • Hideshima T,Ikeda H,Chauhan D,Okawa Y,Raje N,Podar K,Mitsiades C,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.Blood. 2009 Jul 30;114(5):1046-52.
    19436050
  • Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.Multiple myeloma.Lancet. 2009 Jul 25;374(9686):324-39. Review.
    19541364
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.J Clin Oncol. 2009 Jul 20;27(21):3518-25.
    19528374
  • McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.Cancer Res. 2009 Jul 15;69(14):5835-42.
    19584292
  • Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC.The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
    19509164
  • Laubach JP,Mitsiades CS,Roccaro AM,Ghobrial IM,Anderson KC,Richardson PG.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia.Leuk Lymphoma. 2009 May;50(5):694-702. Review.
    19452315
  • Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG.Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.Semin Hematol. 2009 Apr;46(2):166-75. Review.
    19389500
  • Hideshima T,Chauhan D,Kiziltepe T,Ikeda H,Okawa Y,Podar K,Raje N,Protopopov A,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.Blood. 2009 May 21;113(21):5228-36.
    19270264
  • Podar K,Tai YT,Hideshima T,Vallet S,Richardson PG,Anderson KC.Emerging therapies for multiple myeloma.Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. Review.
    19249983
  • Mitsiades CS,Rouleau C,Echart C,Menon K,Teicher B,Distaso M,Palumbo A,Boccadoro M,Anderson KC,Iacobelli M,Richardson PG.Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.Clin Cancer Res. 2009 Feb 15;15(4):1210-21.
    19228727
  • Richardson PG,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Blade J,Boccadoro M,Cavenagh JD,Boral AL,Esseltine DL,Wen PY,Amato AA,Anderson KC,San Miguel J.Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.British Journal of Haematology. 2009 Mar;144(6):895-903.
    19170677
  • Wolf J,Richardson PG,Schuster M,LeBlanc A,Walters IB,Battleman DS.Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.Clin Adv Hematol Oncol. 2008 Oct;6(10):755-60.
    18997666
  • Lee SJ,Richardson PG,Sonneveld P,Schuster MW,Irwin D,San Miguel JF,Crawford B,Massaro J,Dhawan R,Gupta S,Anderson KC.Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.British Journal of Haematology. 2008 Nov;143(4):511-9.
    18986387
  • Jagannath S,Barlogie B,Berenson JR,Siegel DS,Irwin D,Richardson PG,Niesvizky R,Alexanian R,Limentani SA,Alsina M,Esseltine DL,Anderson KC.Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.British Journal of Haematology. 2008 Nov;143(4):537-40.
    18783399
  • Cutler C,Stevenson K,Kim HT,Richardson P,Ho VT,Linden E,Revta C,Ebert R,Warren D,Choi S,Koreth J,Armand P,Alyea E,Carter S,Horowitz M,Antin JH,Soiffer R.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.Blood. 2008 Dec 1;112(12):4425-31.
    18776081
  • San Miguel JF,Schlag R,Khuageva NK,Dimopoulos MA,Shpilberg O,Kropff M,Spicka I,Petrucci MT,Palumbo A,Samoilova OS,Dmoszynska A,Abdulkadyrov KM,Schots R,Jiang B,Mateos MV,Anderson KC,Esseltine DL,Liu K,Cakana A,van de Velde H,Richardson PG.Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.N Engl J Med. 2008 Aug 28;359(9):906-17.
    18753647
  • Lonial S,Richardson PG,San Miguel J,Sonneveld P,Schuster MW,Blade J,Cavenagh J,Rajkumar SV,Jakubowiak AJ,Esseltine DL,Anderson KC,Harousseau JL.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.British Journal of Haematology. 2008 Oct;143(2):222-9.
    18713253
  • Chanan-Khan A,Sonneveld P,Schuster MW,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Neuwirth R,Anderson KC,Richardson PG.Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.J Clin Oncol. 2008 Oct 10;26(29):4784-90.
    18711175
  • Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weler E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.Blood. 2008 Aug 15;112(4):1329-37.
    17906076
  • Niesvizky R,Richardson PG,Rajkumar SV,Coleman M,Rosinol L,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Boral AL,Esseltine DL,Anderson KC,Blade J.The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.British Journal of Haematology. 2008 Sep;143(1):46-53.
    18673366
  • Mitsiades CS,Ocio EM,Pandiella A,Maiso P,Gajate C,Garayoa M,Vilanova D,Montero JC,Mitsiades N,McMullan CJ,Munshi NC,Hideshima T,Chauhan D,Aviles P,Otero G,Faircloth G,Mateos MV,Richardson PG,Mollinedo F,San-Miguel JF,Anderson KC.Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.Cancer Res. 2008 Jul 1;68(13):5216-25.
    18593922
  • Richardson PG,Mitsiades C,Schlossman R,Ghobrial I,Hideshima T,Munshi N,Anderson KC.Bortezomib in the front-line treatment of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. Review.
    18588451
  • Munshi NC,Mitsiades C,Richardson PG,Anderson KC.Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.Nat Clin Pract Oncol. 2008 Jul;5(7):374-5.
    18542118
  • Treister NS, Richardson P, Schlossman R, Miller K, Woo SB.Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jun;105(6):e1-4.
    18417376
  • Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC.Fatty acid synthase is a novel therapeutic target in multiple myeloma.British Journal of Haematology. 2008 May;141(5):659-71.
    18410446
  • Richardson PG.The myeloma landscape in 2008.Clin Adv Hematol Oncol. 2008 Feb;6(2 Suppl 2):1-12; quiz 15-6.
    18347555
  • Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.Clin Cancer Res. 2008 Apr 15;14(8):2387-95.
    18413829
  • Richardson PG, Niesvizky R, Anderson KC, Blade J.Re: When you look matters: the effect of assessment schedule on progression-free survival.Journal of the National Cancer Institute. 2008 Mar 5;100(5):373.
    18314478
  • Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D.Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.Leuk Lymphoma. 2008 Mar;49(3):502-7.
    18297527
  • Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM.Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.Clin Cancer Res. 2008 Feb 1;14(3):865-74.
    18245550
  • Kettler GC, Martiny AC, Huang K, Zucker J, Coleman ML, Rodrigue S, Chen F, Lapidus A, Ferriera S, Johnson J, Steglich C, Church GM, Richardson P, Chisholm SW.Patterns and implications of gene gain and loss in the evolution of Prochlorococcus.PLoS Genet. 2007 Dec;3(12):e231.
    18159947
  • Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC.The malignant clone and the bone-marrow environment.Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612. Review.
    18070708
  • Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG.From the bench to the bedside: emerging new treatments in multiple myeloma.Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816. Review.
    18070720
  • Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC.Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.Blood. 2008 Feb 1;111(3):1654-64.
    18006697
  • Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC.The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.Hematol Oncol Clin North Am. 2007 Dec;21(6):1007-34, vii-viii. Review.
    17996586
  • Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.Management of relapsed and relapsed refractory myeloma.Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. Review.
    17996594
  • Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA.Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.Clin Cancer Res. 2007 Oct 15;13(20):6162-7.
    17947482
  • Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.Novel therapies in myeloma.Curr Opin Hematol. 2007 Nov;14(6):609-15. Review.
    17898564
  • Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC.Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.British Journal of Haematology. 2007 Oct;139(1):55-63.
    17854307
  • Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.British Journal of Haematology. 2007 Sep;138(6):783-91.
    17760810
  • Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC.Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis.Blood. 2007 Sep 1;110(5):1656-63.
    17510321
  • Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.Nat Rev Cancer. 2007 Aug;7(8):585-98. Review.
    17646864
  • Munshi NC, Mitsiades CS, Richardson PG, Anderson KC.Does maintenance therapy with thalidomide benefit patients with multiple myeloma?.Nat Clin Pract Oncol. 2007 Jul;4(7):394-5.
    17534287
  • Ho VT, Linden E, Revta C, Richardson PG.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.Semin Thromb Hemost. 2007 Jun;33(4):373-88. Review.
    17525895
  • Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.British Journal of Haematology. 2007 Jun;137(5):429-35.
    17451408
  • Podar K, Richardson PG, Chauhan D, Anderson KC.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Expert Rev Anticancer Ther. 2007 Apr;7(4):551-66. Review.
    17428175
  • Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S.Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.Blood. 2007 Mar 15;109(6):2604-6.
    17138816
  • Richardson PG, Hideshima T, Mitsiades C, Anderson KC.The emerging role of novel therapies for the treatment of relapsed myeloma.J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.
    17335684
  • Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC.Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.Leukemia. 2007 Mar;21(3):535-40.
    17268521
  • Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP.High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.Biol Blood Marrow Transplant. 2007 Feb;13(2):183-96. Review.
    17241924
  • Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.Blood. 2007 Apr 15;109(8):3177-88.
    17185464
  • Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.Br J Haematol. 2007 Feb;136(3):414-23.
    17173546
  • Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC.Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.Leukemia. 2007 Jan;21(1):151-7.
    17096017
  • Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC.A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood. 2006 Nov 15;108(10):3458-64.
    16840727
  • Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.Cancer Res. 2006 Jul 1;66(13):6675-82.
    16818641
  • Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC,.Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.Haematologica. 2006 Jul;91(7):929-34.
    16818280
  • Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.J Clin Oncol. 2006 Jul 1;24(19):3113-20.
    16754936
  • Mitsiades CS, Richardson PG, Anderson KC.The theraputic use of vitamin K compounds in multiple myeloma.Haematologica. 2006 May;91(5):578b.
    16670056
  • Richardson PG, Schlossman R, Hideshima T, Anderson KC.New treatments for multiple myeloma.Oncology (Huntingt). 2005 Dec;19(14):1781-92; discussion 1792,. Review.
    16506632
  • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.Cancer. 2006 Mar 15;106(6):1316-9.
    16470606
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.Anti-myeloma activity of heat shock protein-90 inhibition.Blood. 2006 Feb 1;107(3):1092-100.
    16234364
  • Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.Blood. 2006 May 15;107(10):4053-62.
    16418332
  • Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Bortezomib: proteasome inhibition as an effective anticancer therapy.Annu Rev Med. 2006;57:33-47. Review.
    16409135
  • Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.Cancer Res. 2006 Jan 1;66(1):184-91.
    16397231
  • Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.Cancer Cell. 2005 Nov;8(5):407-19.
    16286248
  • Richardson PG, Mitsiades CS, Hideshima T, Anderson KC.Novel biological therapies for the treatment of multiple myeloma.Best Pract Res Clin Haematol. 2005;18(4):619-34.
    16026741
  • Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC.Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.Cancer Res. 2005 Jul 1;65(13):5898-906.
    15994968
  • Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med. 2005 Jun 16;352(24):2487-98.
    15958804
  • Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM.Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.Clin Cancer Res. 2005 Jun 15;11(12):4430-6.
    15958627
  • Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC.Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8567-72.
    15937109
  • Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D, Richardson P, Schlossman R, Choi PS, Grogins J, O'Connor PG, Cohen K, Attar EC, Freshman J, Rich R, Mangano JA, Gribben JG, Anderson KC, Scadden DT.Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.Blood. 2005 Mar 1;105(5):2235-8.
    15292069
  • Rajkumar SV, Richardson PG, Hideshima T, Anderson KC.Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Oncol. 2005 Jan 20;23(3):630-9.
    15659509
  • Richardson PG, Mitsiades C, Hideshima T, Anderson KC.Proteasome inhibition in the treatment of cancer.Cell Cycle. 2005 Feb;4(2):290-6.
    15655370
  • Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC.Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br J Haematol. 2005 Jan;128(2):192-203.
    15638853
  • Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ.Routine screening for psychosocial distress following hematopoietic stem cell transplantation.Bone Marrow Transplant. 2005 Jan;35(1):77-83.
    15502851
  • Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC.VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis.Blood. 2004 Nov 1;104(9):2886-92.
    15217829
  • Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol. 2004 May;125(3):343-52.
    15086415
  • Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC.Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.Cancer Res. 2004 Apr 15;64(8):2846-52.
    15087402
  • Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Blood. 2004 Apr 15;103(8):3158-66.
    15070698
  • Hideshima T, Richardson PG, Anderson KC.Targeting proteasome inhibition in hematologic malignancies.Rev Clin Exp Hematol. 2003 Jun;7(2):191-204.
    14763162
  • Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC.Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.Cancer Res. 2003 Dec 1;63(23):8428-36.
    14679006
  • Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.Bone Marrow Transplant. 2003 Dec;32(12):1145-51.
    14647268
  • Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC.GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.Blood. 2004 May 1;103(9):3474-9.
    14644994
  • Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC.Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.Oncogene. 2003 Nov 20;22(52):8386-93.
    14627979
  • Richardson PG, Hideshima T, Anderson KC.Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.Cancer Control. 2003 Sep-Oct;10(5):361-9.
    14581890
  • Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC.Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.Cancer Res. 2003 Oct 1;63(19):6187-94.
    14559802
  • Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC.Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.Cancer Res. 2003 Sep 15;63(18):5850-8.
    14522909
  • LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC.Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.Blood. 2004 Mar 1;103(5):1787-90.
    14512311
  • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med. 2003 Jun 26;348(26):2609-17.
    12826635
  • Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.Blood. 2003 Oct 1;102(7):2615-22.
    12816865
  • Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL.Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.Br J Haematol. 2003 Jun;121(6):842-8.
    12786794
  • Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC.Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.Br J Haematol. 2003 May;121(4):592-6.
    12752100
  • Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ.Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.Blood. 2003 Sep 1;102(5):1578-82.
    12738663
  • Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood. 2003 May 15;101(10):4055-62.
    12531799
  • Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.Cancer Res. 2003 Jan 1;63(1):18-21.
    12517770
  • Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC.Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.Mol Cancer Ther. 2002 Aug;1(10):851-60.
    12492118
  • Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC.Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.Blood. 2003 May 1;101(9):3606-14.
    12480690
  • Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC.The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.Mol Cancer Ther. 2002 May;1(7):539-44.
    12479272
  • Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood. 2003 Mar 15;101(6):2377-80.
    12424198
  • Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC.Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.Blood. 2003 Jan 15;101(2):703-5.
    12393542
  • Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.Blood. 2002 Dec 15;100(13):4337-43.
    12393437
  • Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.Blood. 2003 Feb 15;101(4):1530-4.
    12393500
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.Molecular sequelae of proteasome inhibition in human multiple myeloma cells.Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9.
    12391322
  • Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood. 2002 Nov 1;100(9):3063-7.
    12384400
  • LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC.Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.Cancer Res. 2002 Sep 1;62(17):4996-5000.
    12208752
  • Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.Cancer Res. 2002 Sep 1;62(17):5019-26.
    12208756
  • Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC.2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Blood. 2002 Sep 15;100(6):2187-94.
    12200384
  • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene. 2002 Aug 22;21(37):5673-83.
    12173037
  • Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E.Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.Biol Blood Marrow Transplant. 2002;8(6):326-33.
    12108918
  • Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC.Cytokines modulate telomerase activity in a human multiple myeloma cell line.Cancer Res. 2002 Jul 1;62(13):3876-82.
    12097303
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC.Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood. 2002 Jun 15;99(12):4525-30.
    12036884
  • Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E.The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe.Biol Blood Marrow Transplant. 2002;8(4):198-205.
    12017145
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.Blood. 2002 Jun 1;99(11):4079-86.
    12010810
  • Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC.NF-kappa B as a therapeutic target in multiple myeloma.J Biol Chem. 2002 May 10;277(19):16639-47.
    11872748
  • Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC.Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.Oncogene. 2002 Feb 21;21(9):1346-58.
    11857078
  • Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC.Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.Leukemia. 2001 Dec;15(12):1950-61.
    11753617
  • Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC.Novel therapies targeting the myeloma cell and its bone marrow microenvironment.Semin Oncol. 2001 Dec;28(6):607-12.
    11740818
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.Bone Marrow Transplant. 2001 Sep;28(5):447-54.
    11593317
  • Richardson PG.Basilar artery thrombosis.Emerg Med (Fremantle). 2001 Sep;13(3):367-72.
    11554871
  • Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC.The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.Oncogene. 2001 Jul 27;20(33):4519-27.
    11494147
  • Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.Blood. 2001 Aug 1;98(3):795-804.
    11468181
  • Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC.Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.Blood. 2001 Jul 15;98(2):428-35.
    11435313
  • Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood. 2001 Jul 1;98(1):210-6.
    11418482
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2001 May 15;19(10):2722-30.
    11352965
  • Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res. 2001 Apr 1;61(7):3071-6.
    11306489
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.Bone Marrow Transplant. 2001 Feb;27(3):269-78.
    11277174
  • Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000 Nov 1;96(9):2943-50.
    11049970
  • Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D.Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer.Bone Marrow Transplant. 2000 Jul;26(2):169-76.
    10918427
  • Kraeft SK, Sutherland R, Gravelin L, Hu GH, Ferland LH, Richardson P, Elias A, Chen LB.Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system.Clin Cancer Res. 2000 Feb;6(2):434-42.
    10690521
  • Richardson P, Guinan E.The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches.Br J Haematol. 1999 Dec;107(3):485-93.
    10583247
  • Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E.Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome.J Clin Oncol. 1999 Apr;17(4):1175.
    10561176
  • Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A.The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.Bone Marrow Transplant. 1999 Nov;24(9):939-45.
    10556951
  • Frei E, Elias A, Wheeler C, Richardson P, Hryniuk W.The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.Clin Cancer Res. 1998 Sep;4(9):2027-37.
    9748116